Looking Into The Human Brain On Psilocybin

Psychedelic substances such as psilocybin and Ayahuasca have been used by indigenous people for centuries and may even have been used by our early ancestors. They have long fascinated researchers for their profound effects on human consciousness and mental health. Intense research efforts in the 1950s and 1960s came to an abrupt halt in 1970 when the Controlled Substances Act was passed. The Drug Enforcement Administration classified LSD and many other psychedelics as Schedule I compounds, considered to have “no recognized medicinal value” and a “significant potential for abuse and dependence”. This effectively made them illegal to use in the United States for any purpose. This situation changed radically, when recent advancements in neuroscience, particularly through functional magnetic resonance imaging (fMRI), started to unravel how these substances induce transformative and persistent changes in the brain.

“…some psychedelics may have remarkable therapeutic potential in treating conditions such as depression, addiction, PTSD and end-of-life anxiety.”

In addition to profound effects on consciousness in healthy individuals, recent studies have shown that some psychedelics may have remarkable therapeutic potential in treating conditions such as depression, addiction, PTSD and end-of-life anxiety. These new therapeutic approaches to chronic brain disorders, which have largely been resistant to decades of pharmacological research, have been celebrated as possible therapeutic breakthroughs in psychiatric treatment. These effects stem from their ability to activate serotonin 2A (5-HT2A) receptors in the brain. In clinical trials, a single high dose of psilocybin has led to rapid and sustained relief from symptoms, lasting from hours to weeks.

Studies in rodents have revealed that psychedelics induce changes in neuronal communication, particularly in regions rich in 5-HT2A receptors like the medial frontal lobe and anterior hippocampus. These changes include synaptogenesis (generation of new synaptic contacts between cells), which appears to be crucial for their antidepressant effects. However, translating findings from rodents to humans has limitations due to differences in receptor homology and brain complexity.

“…the precise mechanisms underlying these therapeutic effects remain poorly understood.”

Psilocybin is among several psychedelics being investigated for therapeutic potential in conditions such as depression and post-traumatic stress disorder (PTSD). Despite promising results from previous studies, the precise mechanisms underlying these therapeutic effects remain poorly understood. Understanding how psychedelics affect human brain networks is pivotal for unraveling their therapeutic mechanisms. Studies using fMRI have shown that during the acute effects of psilocybin (lasting about 6 hours), there is increased glutamate signaling, altered glucose metabolism, and reduced electrophysiological signal power. Recent advancements in neuroimaging techniques, such as precision functional mapping using dense functional magnetic resonance imaging (fMRI) sampling, have enabled researchers to track individual-specific changes in brain networks following psilocybin administration. This approach minimizes variability across participants and has highlighted consistent patterns of connectivity alterations induced by psychedelics.

“…psilocybin induced profound and widespread changes in functional connectivity across the cortex and subcortical structures.”

An article published by a team of investigators from Washington University School of Medicine led by Joshua Siegel and published in the prestigious journal Nature on July 17, 2024 describes a series of elegant studies into the effects of psilocybin, the hallucinogenic compound found in magic mushrooms, on the human brain. The study utilized fMRI to track brain activity in seven healthy volunteers before, during, and after ingesting a high dose of psilocybin. This method allowed the researchers to observe how the drug influences networks of neurons across the entire brain over time.

In their study, psilocybin induced profound and widespread changes in functional connectivity across the cortex and subcortical structures. These changes were most prominent in association networks where signals from different regions of the brain are integrated, rather than primary cortical regions. Key findings from the study include the observation that psilocybin caused significant disruptions in the brain’s default mode network (DMN). This network is engaged in the absence of external signals and focused attention and typically governs introspective and self-referential processes. It is active during periods of wakeful rest, such as daydreaming and during meditative practices. Under the influence of psilocybin, the neurons within the DMN became desynchronized, altering their usual patterns of firing. The largest disruptions were observed in DMN-connected areas of the thalamus, basal ganglia, cerebellum, and hippocampus.

The subjective psychedelic experience, measured using instruments like the Mystical Experience Questionnaire (MEQ30), correlated closely with brain changes. In other words, participants reporting more intense mystical experiences also exhibited greater alterations in brain connectivity patterns. This correlation underscored the link between subjective states of consciousness and objective neurobiological changes induced by psychedelics. Importantly, when participants engaged in cognitive tasks during psychedelic states reduced this desynchronization, pointing to context-dependent effects on brain function.

“…this disruption persisted for weeks after the acute effects of psilocybin had worn off…”

Moreover, the study highlighted a prolonged disruption in communication between the DMN and the anterior hippocampus, a brain region crucial for spatial navigation, memory, and the construction of one’s sense of self and time. Remarkably, this disruption persisted for weeks after the acute effects of psilocybin had worn off, consistent with the prolonged subjective effects of the compound. The researchers also noted that techniques like ‘grounding’, which divert attention away from the typical psychedelic drug experience, could mitigate some of these effects, suggesting a potential link between psychological interventions and neurological responses to psychedelics.

While the study sheds light on the immediate neurological effects of psilocybin, it stops short of definitively explaining its therapeutic benefits. For example, there is a need to decipher whether psilocybin’s effects on brain networks directly correlate with its therapeutic potential, or if the subjective psychedelic experience itself induces beneficial changes in brain function. It also doesn’t address the relative importance of psychological context on therapeutic outcomes. For example, it is not known if the psilocybin-induced desynchronization of brain networks makes the patient’s brain more receptive to psychological and behavioral interventions.

“While the acute effects of psilocybin on brain connectivity are well-documented, persistent changes in connectivity have also been observed.”

Specifically, in the current study, decreased functional connectivity between the anterior hippocampus and DMN persisted for weeks after a single dose of psilocybin. This finding aligns with neurobiological models of antidepressant effects and suggests a lasting neuroplastic effect on brain circuitry relevant to mood regulation.

The insights gained from these neuroimaging studies hold significant implications for psychedelic-assisted therapy. By elucidating how psychedelics alter brain function and connectivity, researchers can optimize therapeutic protocols, predict individual treatment responses, and mitigate potential adverse effects. Furthermore, understanding the neural correlates of the psychedelic experience can guide the development of personalized treatment approaches tailored to enhance therapeutic outcomes.

In conclusion, advancements in neuroimaging technologies are providing unprecedented insights into the neurobiological effects of psychedelics on the human brain. These studies are not only unraveling the mechanisms underlying their therapeutic potential but also deepening our understanding of consciousness and brain function. As research continues to evolve, leveraging these findings has the potential to revolutionize psychiatric care and offer new hope for those suffering from treatment-resistant mental health conditions.